Buprenorphine-Clinically useful but often misunderstood

Scandinavian Journal of Pain

Volumn 4, Issue 3, 2013, Pages 148-152

  Butler, Stephen ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Buprenorphine; Delta Receptor agonist; Indications; Kappa Receptor antagonist; Mu Receptor agonist; Opioid receptors; ORL 1 receptor agonist

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NALOXONE; NORSPAN; OPIATE; UNCLASSIFIED DRUG; ZUBSOLV;

CANCER PAIN; CHRONIC PAIN; CLINICAL PRACTICE; DOSE RESPONSE; DRUG ABUSE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; NEUROPATHIC PAIN; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW;

EID: 84880047087     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2013.05.004     Document Type: Review

References (39)

1. Dum J., Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981, 74:627-633.
2. Lizasoain I., Leza J.C., Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its agonist effects. Gen Pharmacol 1991, 22:297-300.
3. Yassen A., Olofsen E., Romberg R., Sarton E., Danhok M., Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006, 104:1232-1242.
4. Christoph T., Kogel B., Schlene K., Méen M., De Vry J., Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005, 507:87-98.
5. Lufty K., Eitan S., Bryant C.D., Yang Y.C., Saliminejad N., Walwyn W., Keifer B.L., Takeshima H., Carroll F.I., Maidment N.T., Evans C.J. Buprenorphine-induced antinociception is mediated by u-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003, 23:10331-10337.
6. Peng H., Huang P., Kehner G.B., Cowan A., Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001, 297:688-695.
7. Pergolizzi J., Aloisi A.M., Dahan A., Filitz J., Lanfford R., Likar R., Mercadante S., Morlion B., Raffe R.B., Sabatowski R., Sacerdote P., Torres L.M., Wienbroum A.A. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Practice 2010, 10:428-450.
8. Kress H.G. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009, 13:219-230.
9. Sitti R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006, 20(Suppl. 1):s25-s30.
10. Kögel B., Christoph T., Straussburger W., Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 2005, 9:559-611.
11. Brown S., Holtzman M., Kim T., Kharash E.D. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 2011, 115:1251-1260.
12. Lufty K., Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004, 2:395-402.
13. Dahan A., Yassan A., Bilj H., Romberg R., Sarton E., Teppema L., Olofsen E., Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006, 96:627-632.
14. Yassan A., Kan J., Olofsen E., Suidqeest E., Dahan A., Danhof M. Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 2005, 313:1136-1149.
15. Kuhlman J.J., Lalani S., Maqluilo J., Levine B., Darwin W.D. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996, 20:369-378.
16. Megarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 2006, 25:79-85.
17. Paronis C., Bergman J. Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. Pharmacol Exp Ther 2011, 336:488-495.
18. Shoblock J.R. The pharmacology of Ro 64-6198, a systemically active, non-peptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 2007, 13:107-136.
19. Chiou L.C., Liau Y.Y., Fan P.C., Kuo P.H., Wang C.H., Riemer C., Prinssen E.P. Nociception/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets 2007, 8:117-135.
20. Zaveri N.T. The nociception/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem 2011, 11:1151-1156.
21. Candido K.D., Hennes J., Gonzales S., Mikat-Stevens M., Pinzur M., Vasic V., Knezevik N.N. Buprenorphine enhances and prolongs the postoperative analgesic effect of bupivacaine in patients receiving infragluteal sciatic nerve block. Anesthesiology 2010, 113:1419-1426.
22. Li B., Chen X.L., Sun C.C., Lu C.Y. The analgesic effect of plexus anesthesia with buprenorphine in patients. Zhonghua Yi Xue Za Zhi 2011, 91:334-336.
23. + channels by the partial u-opioid receptor agonist buprenorphine. Anesthesiology 2012, 116:1335-1346.
24. Plosker G.J., Lyseng-Williamson K.A. Buprenorphine 5, 10 and 20μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs 2011, 71:2491-2509.
25. Vadivela N., Hines R.L. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008, 3:421-430.
26. Bickel W.K., Stitzer M.C., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988, 24:47-53.
27. Yokell M., Zaller N.D., Green T.C., Rich J.D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev 2011, 4:28-41.
28. Manubay J.M., Muchow C., Sullivan M.A. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim Care 2011, 38:71-93.
29. Hans G. Buprenorphine - a review of its role in neuropathic pain. J Opioid Manage 2007, 3:195-206.
30. Induru R.R., Davis M.P. Buprenorphine for neuropathic pain - targeting hyperalgesia. Am J Hosp Palliat Care 2009, 26:470-473.
31. Apolone G., Corli O., Negri E., Mangano S., Montanari M., Greco M.T. Effects of transdermal buprenorphine on patient-reported outcomes in cancer patients: results from the Cancer Pain Outcomes Research (COPR) Study Group. Clin J Pain 2009, 25:671-682.
32. Mercadante S., Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systemic review. Palliat Med 2011, 25:504-515.
33. Ducharme S., Frazer R., Gill K. Update on the clinical use of buprenorphine in opioid related disorders. Can Fam Physician 2012, 58:37-41.
34. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, CD002207.
35. Schottenfeld R.S., Pakes J., O'Connor P., Chawarski M., Oliveto A. Thrice weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000, 47:1072-1079.
36. Cicero T.J., Inciardi A., Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain 2005, 6:662-672.
37. Wedan E.F., Bigelow G.E., Johnson R.E., Nuzzo P.A., Haigney A.C. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007, 167:2469-2475.
38. Ceccarelli I., De Padova A.M., Fiorenzani P., Massafra C., Aloisi A.M. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience 2006, 140:929-937.
39. Davis M.P. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012, 10:209-219.